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Abstract
Sputum cultures are an important tool in monitoring the response to tuberculosis treatment, especially in multidrug-
resistant tuberculosis. There has, however, been little study of the effect of treatment regimen composition on culture
conversion. Well-designed clinical trials of new anti-tuberculosis drugs require this information to establish optimized
background regimens for comparison. We conducted a retrospective cohort study to assess whether the use of an
aggressive multidrug-resistant tuberculosis regimen was associated with more rapid sputum culture conversion. We
conducted Cox proportional-hazards analyses to examine the relationship between receipt of an aggressive regimen for the
14 prior consecutive days and sputum culture conversion. Sputum culture conversion was achieved in 519 (87.7%) of the
592 patients studied. Among patients who had sputum culture conversion, the median time to conversion was 59 days (IQR:
31–92). In 480 patients (92.5% of those with conversion), conversion occurred within the first six months of treatment.
Exposure to an aggressive regimen was independently associated with sputum culture conversion during the first six
months of treatment (HR: 1.36; 95% CI: 1.10, 1.69). Infection with human immunodeficiency virus (HR 3.36; 95% CI: 1.47,
7.72) and receiving less exposure to tuberculosis treatment prior to the individualized multidrug-resistant tuberculosis
regimen (HR: 1.58; 95% CI: 1.28, 1.95) were also independently positively associated with conversion. Tachycardia (HR: 0.77;
95% CI: 0.61, 0.98) and respiratory difficulty (HR: 0.78; 95% CI: 0.62, 0.97) were independently associated with a lower rate of
conversion. This study is the first demonstrating that the composition of the multidrug-resistant tuberculosis treatment
regimen influences the time to culture conversion. These results support the use of an aggressive regimen as the optimized
background regimen in trials of new anti-TB drugs.
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Introduction
Sputum cultures are an important tool in monitoring the
response to tuberculosis (TB) treatment, especially in multidrug-
resistant TB (MDR-TB). Cultures are usually obtained on a
monthly basis while under therapy, if resources are available [1].
Sputum culture conversion—the transition in sputum culture
results from a positive sample growing Mycobacterium tuberculosis
to two consecutive negative cultures separated by at least 30 days
—is a key clinical milestone signifying that the patient is
responding to therapy [2,3].
It is known that culture conversion can be delayed in the
treatment of MDR-TB compared to drug-susceptible disease [4].
Risk factors for delayed culture conversion during MDR-TB
therapy include markers of advanced pulmonary disease, specif-
ically smear positivity [5,6] and the presence of cavitary lung
lesions [7]. Culture conversion has also been shown to occur more
slowly in patients with resistance to second line anti-TB drugs
[8,9]. More recently, co-morbidities like low body weight [10] and
smoking [11] have been linked to delayed conversion.
There has, however, been little study of the effect of treatment
regimen composition on culture conversion. In addition to the
potential benefits for patient care, such information is also critical
to the design of MDR-TB treatment trials [12]. Pivotal phase II
studies of the new anti-TB drugs bedaquiline and delamanid used
designs that compared sputum culture conversion in patients who
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e108035received the standard-of-care—also known as the optimized
background regimen—and placebo to patients who received the
optimized background regimen plus the investigational agent
[13,14]. The percentage of participants in the placebo arm whose
sputum culture converted at two months was different between the
two studies, but reasons for this difference have not been clearly
discerned. Differing composition of the optimized background
regimen is one possible explanation.
We conducted a retrospective cohort study to assess whether
treatment regimen composition, particularly whether an aggressive
regimen containing five likely effective drugs including a
fluoroquinolone and an injectable agent during the intensive
phase was associated with accelerated sputum culture conversion.
Methods
Study population
The study population comprised patients starting treatment for
MDR-TB in Lima, Peru, during the period 1 February 1999 to 31
July 2002. Patients were included in the analysis if the regimen
they received during the study period was their first regimen
individualized to drug susceptibility test results. Patients were
excluded if they did not have a positive culture at the start of
treatment or if they had a positive culture followed by a negative
culture prior to the start of treatment. Patients were also excluded
if data were not available about the composition of their
individualized MDR-TB treatment regimen.
The approach to drug susceptibility testing (DST), treatment
and monitoring in this cohort has been previously described [15].
All DST was performed at or under the guidance of a
supranational reference laboratory. Isolates were routinely tested
for isoniazid, rifampin, pyrazinamide, ethambutol, and strepto-
mycin susceptibility. Second-line DST (amikacin, capreomycin,
cycloserine, ethionamide, kanamycin, para-aminosalacylic acid,
ciprofloxacin or ofloxacin and either gatifloxacin, levofloxacin or
moxifloxacin) was also performed on a majority of the patients.
These DST results as well as any prior anti-TB drug exposure
were taken into account when formulating the treatment regimen
[16].
Patients were closely monitored during treatment. Directly
observed therapy was provided by local community health workers
and program nurses. Adverse events were managed in consultation
with supervising physicians from the Peruvian National TB
Program. Additionally, patients were given nutritional, psycho-
logical and financial supports while on treatment.
Primary exposure and covariates
The primary exposure was receipt of an aggressive treatment
regimen, examined as a time-varying variable. An aggressive
regimen is an MDR-TB treatment composed of at least five likely
effective anti-TB agents, including a fluoroquinolone, and in the
intensive phase, an injectable agent [15]. Injectable agents
included streptomycin, kanamycin, amikacin and capreomycin.
Fluoroquinolones included ciprofloxacin, ofloxacin, levofloxacin
or moxifloxacin. Agents were classified as likely effective if the
baseline phenotypic DST showed no evidence of resistance to that
agent or, if DST was not available, if the patient had less than one
month of exposure to the drug prior to starting the MDR-TB
regimen.
Exposure was defined daily, based on receipt of the aggressive
regimen for the prior 14 days: if the treatment met the definition of
aggressive on all of the previous 14 days, that patient-day was
considered exposed. (Figure 1 illustrates an example of exposure
classification.) Exposure status was recalculated—and could
change—on each day that the patient was on treatment through
the entire treatment period until culture conversion or censoring.
We chose a 14-day exposure interval reasoning that it is a plausible
period in which to expect conversion [17]. Exposure intervals
shorter than 14 days were rejected given concerns that second-line
anti-TB drugs are generally considered less efficacious compared
to first-line therapy. Covariates included demographic variables,
prior TB treatment, date of treatment, indicators of disease
severity, and comorbidities.
Outcome definition
The primary outcome was time to sputum culture conversion.
Sputum culture conversion was defined as two consecutive
negative cultures separated by at least 30 days. The date of
sputum culture conversion was the date of the first of two
consecutive sputum cultures to be recorded as negative in a patient
who had culture-converted [2].
Statistical analysis
We conducted Cox proportional-hazards analyses, stratified by
day of treatment using the Anderson-Gill formulation [18,19], to
examine the relationship between receipt of an aggressive regimen
for 14 prior consecutive days and time to sputum culture
conversion. Individuals without culture conversion were censored
on the earlier of their last culture date or treatment outcome date.
To account for possible informative censoring by death, we
adjusted for variables that had been associated with mortality in a
previous analysis of this cohort: age, female gender, HIV infection,
at least one comorbidity other than HIV, the number of resistant
agents at baseline, having received less than two previous regimens
or a standardized MDR-TB regimen, tachycardia, low BMI, and
extrapulmonary TB [15]. Additionally, we adjusted for all other
covariates shown in Table 1 and removed them using a manual
backward selection approach if they did not predict the outcome at
a p- value #0.20 and if removal did not alter the hazard ratio for
the aggressive regimen variable by .10%. For multivariable
analysis, missing values were multiply imputed using Markov
Chain Monte Carlo methods to complete the dataset. We
examined potential violations of the proportional hazards
assumption by including an interaction term between receipt of
an aggressive regimen and time since the start date of the MDR-
TB regimen (1–6, 7–12, .12 months). This allowed us to assess
the presence of effect modification by time.
Data collection and availability
Data were collected and recorded in a web-based electronic
medical record during treatment. A standardized chart abstraction
was conducted to complete the dataset. Data has been deposited in
a public repository at the Harvard Dataverse (doi: 10.7910/DVN/
27020).
Ethics statement
The parent study was first approved by the Institutional Review
Board at Harvard Medical School and by the Ministry of Health
of Peru in 2000. At the time of the reviews, the informed consent
form used routinely by the Peruvian National Tuberculosis
Program for MDR-TB patients was deemed to be sufficient. As
a result, no waiver was obtained. The authors had no access to
identifying information during the current study or previous
parent study. Data was anonymized prior to analysis.
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We found 673 patients available for analysis. Eighty-one
patients were excluded: two because they had already received
an individualized regimen for MDR-TB, two for incomplete
treatment regimen data and 77 because they did not have a
positive culture prior to the initiation of the individualized MDR-
TB regimen or because a more recent negative culture followed
the positive culture that preceded the start of the individualized
MDR-TB regimen. A total of 592 patients were analyzed.
Baseline characteristics of the study cohort are presented in
Table 1. Two hundred and twenty seven (38.3%) patients were
female. The median age was 28.7 (inter-quartile range [IQR]:
23.0–37.8) years. Drug resistance was common in the cohort, with
Figure 1. Illustration of daily exposure status defined by receipt of an aggressive regimen in the 14 days prior (example of three
patients assessed at day 44 of treatment).
doi:10.1371/journal.pone.0108035.g001
Table 1. Distribution of covariates at initiation of the individualized MDR-TB regimen.
COVARIATE N Patients with specified characteristics
N (%) or Median (IQR)
PRIOR TREATMENT
Received #2 previous regimens without prior standardized regimen for MDR-TB 592 160 (27.0)
DEMOGRAPHICS
Female 592 227 (38.3)
Age 592 28.7 (23.0–37.8)
Enrolled in Northern Lima 592 252 (42.6)
Enrolled prior to March 1, 2001* 592 135 (22.8)
INDICATORS OF SEVERITY
Bilateral, cavitary findings 568 314 (55.3)
Low BMI or malnutrition
` 508 190 (37.4)
Low hematocrit
J 521 249 (47.8)
Tachycardia 578 169 (29.2)
Respiratory difficulty
¥ 563 404 (71.8)
Extrapulmonary TB 592 46 (7.8)
Number of resistant agents 592 5 (4–7)
Lab-confirmed XDR-TB
£ 577 45 (7.8)
Prior resective surgery 579 16 (2.8)
COMORBITIES
Patients with at least one comorbidity
1 573 206 (36.0)
HIV infection 583 7 (1.2)
*Patients enrolled prior to March 1, 2001 were more likely to have received the standard Category II retreatment regimen after failure of Category I than patients
enrolled after this date, when national policy changed.
`,18.5 in women, ,20 in men; or malnutrition established clinically.
J#30% in women, #36% in men; when missing, also used hemoglobin #10 in women and #12 in men.
¥Dyspnea; resting heart rate .26/minute.
£Isolate resistant to at least isoniazid, rifampin, fluoroquinolone, and injectable (kanamycin, capreomycin or amikacin).
1This includes the following comorbidities: cardiovascular disease (12), diabetes (15), hepatitis or cirrhosis (7), epilepsy/seizures (10), renal insufficiency (6), psychiatric
disorder (101), ever smoked (59), ever used/abused alcohol or other substance (49).
doi:10.1371/journal.pone.0108035.t001
Culture Conversion and MDR-TB Regimen Composition
PLOS ONE | www.plosone.org 3 September 2014 | Volume 9 | Issue 9 | e108035cultures resistant to a median of five (IQR 4–7) drugs. There were
45 (7.8%) patients who had extensively drug-resistant TB.
Advanced pulmonary disease was also common: 404 (71.8%)
patients had respiratory difficulty at treatment initiation and 314
(55.3%) patients had bilateral or cavitary disease on chest
radiograph. Co-morbidities were present in 206 (36.0%) patients.
Only seven (1.2%) patients, however, had HIV co-infection.
Sputum culture conversion was achieved in 519 patients
(87.7%). Among patients who had sputum culture conversion,
the median time to sputum conversion was 59 days (IQR: 31–92).
In 480 patients (92.5% of those with conversion), conversion
occurred within the first six months of treatment. The rate of
conversion was highest in months 0–6, after which time the rate
was notably lower (Table 2).
In univariate analysis, exposure to an aggressive regimen was
significantly associated with sputum culture conversion (hazard
ratio [HR] 1.40; 95% confidence interval [CI] 1.17, 1.67).
In our assessment of the proportional hazards assumption, we
observed effect modification by time since MDR-TB treatment
initiation. Specifically, we noted that the association between an
aggressive regimen and culture conversion varied by time since
treatment initiation (0–6 months, 6–12 months, .12 months)
(Figure 2). In multivariable analysis, exposure to an aggressive
regimen was independently associated with sputum culture
conversion during the first six-months of treatment (HR: 1.36;
95% CI: 1.10, 1.69), but not during months 6–12 of treatment
(HR: 0.95; 95% CI: 0.42, 2.15) or after 12 months of treatment,
(HR: 0.39; 95% CI: 0.12, 1.24; likelihood ratio p-value for
interaction with time on treatment: 0.09) (Table 3).
All subsequent results are from the model that accounts for the
effect modification. Infection with HIV (HR 3.36; 95% CI: 1.47,
7.72), and receiving less exposure to TB treatment prior to the
individualized MDR-TB regimen (HR: 1.58; 95% CI: 01.28, 1.95)
were also independently positively associated with conversion.
Tachycardia (HR: 0.77; 95% CI: 0.61, 0.98) and respiratory
difficulty (HR: 0.78; 95% CI: 0.62, 0.97) were independently
associated with a lower rate of conversion.
Discussion
We found that patients treated for MDR-TB had higher rates of
sputum culture conversion if they received an aggressive regimen
for MDR-TB for the 14 preceding consecutive days compared to
those who did not. To our knowledge, this is the first report to
demonstrate an association between regimen composition and
time to culture conversion in the treatment of MDR-TB.
Infection with HIV was also associated with more rapid sputum
conversion. This finding may be related to the pauci-bacillary state
of HIV and TB coinfection, with lower amounts of TB bacilli per
milliliter of sputum in patients with HIV infection [20]. Sputum
culture conversion was also more likely if the patient had not
received more than two previous regimens or a standardized
MDR-TB regimen, highlighting the importance of prompt receipt
of appropriate treatment for MDR-TB.
In contrast, indicators of advanced pulmonary disease like
respiratory difficulty and tachycardia were associated with lower
rates of conversion, possibly because of higher bacterial burdens in
those patients. Alternatively, patients with advanced disease may
also have damaged lung parenchyma, thereby limiting the
penetration of drug into the most diseased tissue. It has been
previously shown that cavitary disease also influences rates of
conversion [7,21].
We found that culture conversion rates were higher in the first
six months of treatment compared to later. High rates of culture
conversion within the first six months of effective MDR-TB
treatment have also been shown in the past [22]. One possible
explanation for lower conversion rates later in treatment is that
patients who did not convert in the first six months may have been
sicker and less likely to experience conversion on any regimen.
Our observation that indicators of severe disease were associated
with delayed conversion supports this explanation. We further
observed that an aggressive regimen did not confer the same
benefit later in therapy. The apparent waning of the aggressive
regimen’s effect on culture conversion over time during treatment
may be related to the gradual depletion of individuals who are
likely to benefit from an aggressive regimen.
From these findings, we posit that there is a majority of patients
for whom the aggressive regimen will shorten the time to culture
conversion. Because the transition from the injectable-based
intensive phase of MDR-TB treatment to the continuation phase
depends on culture conversion, the aggressive regimen may carry
a potential benefit in shortening the duration of the intensive
phase, thereby limiting the toxicity and programmatic costs
associated with this part of treatment.
There are, however, other patients who may not convert in the
first six months of treatment using current MDR-TB regimens.
Further characterization of these patients with delayed conversion
is needed to determine potential causes of persistent culture
positivity. For patients who do not convert in the first six months,
additional strategies/interventions may be needed to effect
conversion. Some of these additional interventions include
enhanced adherence support, aggressive management of adverse
events, and consideration of resective surgery.
Interest in using culture conversion as a surrogate clinical
endpoint is mounting because of its potential to shorten the time
under observation in clinical trials of new anti-TB drugs [23,24].
The favored approach to investigating activity of new drugs
against MDR-TB has been to add either placebo or a new agent to
an optimized background regimen and compare rates of culture
conversion [25]. Two recent studies revealed the benefit conferred
by the addition of investigational agents using this method [13,14].
There was, however, considerable variability in the composition of
the optimized background regimens: one was standardized,
comprising kanamycin, ofloxacin, prothionamide, terizidone and
pyrazinamide, while the other was individualized in accordance
Table 2. Rates of sputum culture conversion in patients receiving individualized MDR-TB regimens, by treatment semester.
Time since start of MDR-TB regimen Conversions Total person-time (months) Rate per 100 person months [95% CI]
0–6 months 480 1514.6 31.7 [29.0, 34.6]
7–12 months 26 258.0 10.1 [6.7, 14.5]
.12 months 13 265.9 4.9 [2.7, 8.1]
doi:10.1371/journal.pone.0108035.t002
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culture conversion among participants in the control arms of the
two studies was also very different; in the former, only 9% of
patients converted at two months, while in the latter, 30%
converted. Our results reveal that regimen composition can be a
chief source of such variability in early treatment response,
independent of other sources, and raises the possibility that a
portion of the difference in conversion in the aforementioned
studies may have been due to the composition of the background
regimen. The implication of such a finding is that the benefit of a
new drug may be overestimated if it is added to a weak
background regimen.
In our study, there exists the possibility of misclassification of the
exposure by defining exposure as receipt of 14 consecutive days of
the aggressive regimen. Patients who had received an aggressive
regimen during most but not all of the 14-day window may still
have benefited, but they were classified as unexposed. We would
expect that this misclassification would attenuate the observed
hazard ratio for the aggressive regimen variable.
Although this study was conducted among patients with
significant prior treatment exposure, including to second-line
drugs, our conclusion—aggressive regimens accelerate conver-
sion—should be generalizable to patient populations with differing
patterns of prior exposure and other baseline characteristics. The
Figure 2. Aggressive regimens are associated with unadjusted rates of culture conversion in the first six months of treatment.
doi:10.1371/journal.pone.0108035.g002
Table 3. Multivariable proportional-hazards analysis of aggressive regimen and sputum culture conversion.
Variable Hazard ratio, multivariable analysis 95% CI, multivariable analysis P value
Aggressive regimen for 14 prior consecutive days
1–6 of treatment 1.36 1.10, 1.69 0.005
7–12 of treatment 0.95 0.42, 2.15 0.93
after 12 months of treatment 0.39 0.12, 1.24 0.11
Female 0.90 0.75, 1.09 0.27
Age 1.00 0.99, 1.01 0.76
At least one comorbidity, other than HIV 0.85 0.70, 1.03 0.10
HIV 3.36 1.47, 7.72 0.004
Number of resistant agents 0.94 0.88, 1.00 0.07
Tachycardia 0.77 0.61, 0.98 0.03
Low BMI or malnutrition 0.87 0.70, 1.08 0.20
Extrapulmonary TB 0.94 0.65, 1.37 0.76
Received # previous regimens without prior
standardized regimen for MDR-TB
1.58 1.28, 1.95 ,0.0001
Low hematocrit 0.85 0.69, 1.03 0.10
Respiratory difficulty 0.78 0.62, 0.97 0.02
Treatment period 0.83 0.67, 1.03 0.09
doi:10.1371/journal.pone.0108035.t003
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accurate information about prior treatment exposure with
cautious interpretation of DST when deciding which agents are
likely to be effective against the infecting strain. Although the
magnitude of the benefit may vary across populations, the
application of these principles is likely to improve outcomes
independently of the distribution of baseline characteristics.
We have now demonstrated that culture conversion in MDR-
TB can be influenced by the component anti-TB drugs in a
treatment regimen. Specifically, we have shown that an aggressive
regimen for MDR-TB is significantly associated with accelerated
culture conversion, which adds to a growing body of knowledge on
the benefits of this regimen including reduced risk of death [15],
failure [26], and relapse [27]. This cumulative evidence suggests
that aggressive regimens with at least five likely effective drugs
including an injectable and fluoroquinolone should be considered
the standard of care in the treatment of patients with MDR-TB.
Further, optimized background regimens in treatment trials should
be constructed to meet this new standard of care. In this way, the
comparison group will receive a treatment known to achieve the
best possible outcome, including the most rapid rate of culture
conversion, thereby establishing a benchmark upon which
experimental regimens must seek to improve.
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